Organ-Specific Therapeutic Effect of Paclitaxel and Carboplatin Chemotherapy After Platinum-Based Chemotherapy and Pembrolizumab for Metastatic Urothelial Carcinoma

Figures & data

Table 1 Patients’ Characteristics

Characteristics	TC Chemotherapy (n=8)
Gender, male sex, n (%)	5 (62.5)
Median age, year (range)	65 (57–79)
ECOG PS, n (%)
0	3 (37.5)
1	2 (25.0)
≥2	3 (37.5)
Primary tumor site, n (%)
Bladder	2 (25.0)
Upper urinary tract	2 (25.0)
Bladder + upper urinary tract	4 (50.0)
Pure UC in histologic testing, no. (%)	8 (100)
Hb <10g/dl, no. (%)	3 (37.5)
Albumin <4.1 g/dl, no. (%)	6 (75.0)
LDH >222 U/L, no. (%)	4 (50.0)
Number of therapies before Pem
1	5 (62.5)
2	2 (25)
3	1 (12.5)
Median duration from the first-line chemotherapy, month (95% CI)	13.1 (5.4–46.7)
Metastasis sites, n (%)
Lymph nodes only	1 (12.5)
Visceral disease	7 (87.5)

Abbreviations: TC, paclitaxel and carboplatin; ECOG PS, Eastern Cooperative Oncology Group Performance Status; UC, urothelial carcinoma; Hb, hemoglobin; LDH, lactate dehydrogenase; Pem, pembrolizumab; CI, confidence interval.

Figure 1 Overall survival of TC chemotherapy.

Table 2 Organ-Specific Responses to TC Chemotherapy

Metastatic Organ	Lymph Node	Lung	Liver	Bone	Primary
	(n=5)	(n=4)	(n=3)	(n=3)	(n=3)
Number of tumor lesions	8	13	14	12	3
Median tumor size, mm (range)	20 (16–65)	14 (6–27)	24 (12–84)	19 (11–40)	47 (17–92)
ORR, %	40	50	64	0	0
CR, n (%)	0	0	0	0	0
PR, n (%)	2 (40)	2 (50)	2 (64)	0	0
SD, n (%)	3 (60)	2 (50)	1 (33)	3 (100)	3 (100)
PD, n(%)	0	0	0	0	0

Abbreviations: ORR, objective response rate; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.

Table 3 Organ-Specific Responses to TC Chemotherapy Compared with Pembrolizumab

Lymph Node (n=5)
Treatment	Pem	TC
RECIST	SD	SD
	PD	PR
	PD	SD
	SD	PR
	PR	SD
Lung (n=4)
Treatment	Pem	TC
RECIST	PD	SD
	PD	PR
	PD	SD
	SD	PR
Liver (n=3)
Treatment	Pem	TC
RECIST	PD	SD
	PD	PR
	PR	PR
Bone (n=3)
Treatment	Pem	TC
RECIST	SD	SD
	SD	SD
	SD	SD
Primary (n=3)
Treatment	Pem	TC
RECIST	PD	SD
	PD	SD
	PD	SD

Abbreviations: TC, paclitaxel and carboplatin; Pem, pembrolizumab; PR, partial response; SD, stable disease; PD, progressive disease.